Wall Street Analyst Initiated Allogene Therapeutics Inc [ALLO]. What else is Wall St. saying


Allogene Therapeutics Inc [NASDAQ: ALLO] price surged by 9.42 percent to reach at $0.21.

The one-year ALLO stock forecast points to a potential upside of 79.25. The average equity rating for ALLO stock is currently 1.61, trading closer to a bullish pattern in the stock market.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Guru’s Opinion on Allogene Therapeutics Inc [ALLO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALLO shares is $11.76 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALLO stock is a recommendation set at 1.61. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Allogene Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 31, 2024. The new note on the price target was released on January 05, 2024, representing the official price target for Allogene Therapeutics Inc stock.

The Average True Range (ATR) for Allogene Therapeutics Inc is set at 0.20, with the Price to Sales ratio for ALLO stock in the period of the last 12 months amounting to 3918.64. The Price to Book ratio for the last quarter was 0.90, with the Price to Cash per share for the same quarter was set at 1.84.

ALLO Stock Performance Analysis:

Allogene Therapeutics Inc [ALLO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.06. With this latest performance, ALLO shares dropped by -5.79% in over the last four-week period, additionally sinking by -16.15% over the last 6 months – not to mention a drop of -49.27% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALLO stock in for the last two-week period is set at 44.51, with the RSI for the last a single of trading hit 48.47, and the three-weeks RSI is set at 42.14 for Allogene Therapeutics Inc [ALLO]. The present Moving Average for the last 50 days of trading for this stock 2.85, while it was recorded at 2.37 for the last single week of trading, and 3.38 for the last 200 days.

Insight into Allogene Therapeutics Inc Fundamentals:

Allogene Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.80 and a Current Ratio set at 12.80.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Allogene Therapeutics Inc go to 1.00%.

Allogene Therapeutics Inc [ALLO] Institutonal Ownership Details

The top three institutional holders of ALLO stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in ALLO stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in ALLO stock with ownership which is approximately 5.8386%.